Fortrea Holdings Inc. (FTRE): Capital Expenditures
$25.20M
Year ended 2025-12-31
$31.80M
Trailing 12 months to 2026-06-30
-22.6%
3-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $25.20M | -1.2% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $25.50M | -36.7% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $40.30M | -25.9% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $54.40M | +105.3% | 2025-03-03, From 2022-01-01 |
| 2021-12-31 | $26.50M | n/a | 2024-03-13, From 2021-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Fortrea Holdings Inc. (FTRE) | 2025-12-31 | $25.20M | -1.2% |
| Natera, Inc. (NTRA) | 2025-12-31 | $106.19M | +59.9% |
| Guardant Health, Inc. (GH) | 2025-12-31 | $48.31M | +37.7% |
| Caris Life Sciences, Inc. (CAI) | 2025-12-31 | $16.26M | +92.6% |
| Quest Diagnostics Inc (DGX) | 2025-12-31 | $527.00M | +24.0% |
| Labcorp Holdings Inc. (LH) | 2025-12-31 | $434.50M | -11.3% |
| Veracyte, Inc. (VCYT) | 2025-12-31 | $9.68M | -14.3% |
| Castle Biosciences Inc (CSTL) | 2025-12-31 | $36.02M | +27.2% |
| Fulgent Genetics, Inc. (FLGT) | 2025-12-31 | $22.57M | -44.0% |
Compare FTRE, NTRA, GH, CAI side by side · Screen every company in Services-Medical Laboratories ↗